Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate)
## Overview
Hepamerz is a combination of two amino acids, L-ornithine and L-aspartate, believed to promote ammonia detoxification in the liver.
## Primary Indications
Hepatic encephalopathy (HE) associated with hyperammonemia.
## Adult Dosing
* **Oral:** 3 grams (e.g., 1 sachet or 3 tablets) three times daily. The total daily dose can range from 9 to 18 grams, divided into three doses.
* **Intravenous (IV):** Typically administered as an infusion. Common regimens include 5 grams IV daily, or up to 10 grams IV twice daily, depending on the severity of HE. Specific IV dosing and infusion rates are often guided by institutional protocols and patient response.
## Pediatric Dosing
* Limited data available for pediatric use. Dosing should be individualized by a specialist and based on clinical response and tolerance.
## Dose Adjustments
* No specific dose adjustments are generally recommended for renal or hepatic impairment, but caution and close monitoring are advised, especially in severe cases.
## Contraindications
* Severe kidney disease (creatinine clearance < 30 mL/min).
* Hypersensitivity to L-ornithine, L-aspartate, or any component of the formulation.
## Adverse Effects
Common: Nausea, vomiting, abdominal discomfort, diarrhea.
Less Common: Dizziness, headache, fatigue.
## Key Drug Interactions
No significant drug interactions are well-established.
## Monitoring
* Monitor for signs and symptoms of hepatic encephalopathy.
* Assess for gastrointestinal side effects.
* Electrolyte and renal function may be monitored in patients with underlying conditions.
## Clinical Pearls
* The efficacy of Hepamerz in HE can vary. It is often used as adjunctive therapy alongside other management strategies.
* Oral formulations are available in sachets (powder to be dissolved in water) and tablets.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*